Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
J Alzheimers Dis ; 70(4): 1259-1274, 2019.
Article in English | MEDLINE | ID: mdl-31322556

ABSTRACT

Alzheimer's disease (AD) pathology consists of extracellular deposits of amyloid-ß peptides (Aß) and intracellular neurofibrillary tangles. These pathological alterations are accompanied by a neuroinflammatory response consisting of increased expression of inflammatory mediators. An anti-inflammatory strategy designed to prevent or delay the development of AD would benefit from knowing when neuroinflammation appears in the transgenic models during prodromal disease stages relative to Aß pathology. We investigated the expression patterns of inflammatory mediators in the brain of 5xFAD mice in comparison to development of Aß deposition. Expression changes in inflammatory mediators and glial markers are more robust in female mice starting at three months of age, in contrast to males in which there is no clear trend through five months. Female and male 5xFAD mice also displayed an age-dependent increase in cortical Aß deposition congruent with neuroinflammation. Thus, in the 5xFAD mouse model of AD, administration of an anti-inflammatory agent would be most efficacious when administered before three months of age.


Subject(s)
Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Inflammation Mediators/metabolism , Prodromal Symptoms , Sex Characteristics , Amyloid beta-Peptides/genetics , Amyloid beta-Peptides/metabolism , Animals , Female , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neurofibrillary Tangles/genetics , Neurofibrillary Tangles/metabolism
2.
eNeuro ; 5(2)2018.
Article in English | MEDLINE | ID: mdl-29766039

ABSTRACT

The efficacy of benzodiazepines to terminate electrographic status epilepticus (SE) declines the longer a patient is in SE. Therefore, alternative methods for ensuring complete block of SE and refractory SE are necessary. We compared the ability of diazepam and a subanesthetic dose of urethane to terminate prolonged SE and mitigate subsequent pathologies. Adult Sprague Dawley rats were injected with diisopropylfluorophosphate (DFP) to induce SE. Rats were administered diazepam (10 mg/kg, ip) or urethane (0.8 g/kg, s.c.) 1 h after DFP-induced SE and compared to rats that experienced uninterrupted SE. Large-amplitude and high-frequency spikes induced by DFP administration were quenched for at least 46 h in rats administered urethane 1 h after SE onset as demonstrated by cortical electroencephalography (EEG). By contrast, diazepam interrupted SE but seizures with high power in the 20- to 70-Hz band returned 6-10 h later. Urethane was more effective than diazepam at reducing hippocampal neurodegeneration, brain inflammation, gliosis and weight loss as measured on day 4 after SE. Furthermore, rats administered urethane displayed a 73% reduction in the incidence of spontaneous recurrent seizures after four to eight weeks and a 90% reduction in frequency of seizures in epileptic rats. By contrast, behavioral changes in the light/dark box, open field and a novel object recognition task were not improved by urethane. These findings indicate that in typical rodent SE models, it is the return of SE overnight, and not the initially intense 1-2 h of SE experience, that is largely responsible for neurodegeneration, accompanying inflammation, and the subsequent development of epilepsy.


Subject(s)
Anesthetics, General/pharmacology , Anticonvulsants/pharmacology , Diazepam/pharmacology , Gliosis/drug therapy , Hippocampus/drug effects , Inflammation/drug therapy , Neurodegenerative Diseases/drug therapy , Status Epilepticus/drug therapy , Status Epilepticus/physiopathology , Urethane/pharmacology , Anesthetics, General/administration & dosage , Animals , Anticonvulsants/administration & dosage , Diazepam/administration & dosage , Disease Models, Animal , Electrocorticography , Enzyme Inhibitors/toxicity , Gliosis/chemically induced , Inflammation/chemically induced , Isoflurophate/toxicity , Neurodegenerative Diseases/chemically induced , Rats , Rats, Sprague-Dawley , Status Epilepticus/chemically induced , Urethane/administration & dosage
3.
Neuropharmacology ; 110(Pt A): 419-430, 2016 11.
Article in English | MEDLINE | ID: mdl-27477533

ABSTRACT

Survivors of exposure to an organophosphorus nerve agent may develop a number of complications including long-term cognitive deficits (Miyaki et al., 2005; Nishiwaki et al., 2001). We recently demonstrated that inhibition of the prostaglandin E2 receptor, EP2, attenuates neuroinflammation and neurodegeneration caused by status epilepticus (SE) induced by the soman analog, diisopropylfluorophosphate (DFP), which manifest within hours to days of the initial insult. Here, we tested the hypothesis that DFP exposure leads to a loss of cognitive function in rats that is blocked by early, transient EP2 inhibition. Adult male Sprague-Dawley rats were administered vehicle or the competitive EP2 antagonist, TG6-10-1, (ip) at various times relative to DFP-induced SE. DFP administration resulted in prolonged seizure activity as demonstrated by cortical electroencephalography (EEG). A single intraperitoneal injection of TG6-10-1 or vehicle 1 h prior to DFP did not alter the development of seizures, the latency to SE or the duration of SE. Rats administered six injections of TG6-10-1 starting 90 min after the onset of DFP-induced SE could discriminate between a novel and familiar object 6-12 weeks after SE, unlike vehicle treated rats which showed no preference for the novel object. By contrast, behavioral changes in the light-dark box and open field assays were not affected by TG6-10-1. Delayed mortality after DFP was also unaffected by TG6-10-1. Thus, selective inhibition of the EP2 receptor may prevent SE-induced memory impairment in rats caused by exposure to a high dose of DFP.


Subject(s)
Indoles/pharmacology , Memory Disorders/prevention & control , Nootropic Agents/pharmacology , Receptors, Prostaglandin E, EP2 Subtype/antagonists & inhibitors , Recognition, Psychology/drug effects , Status Epilepticus/drug therapy , Animals , Anxiety/drug therapy , Anxiety/metabolism , Brain/drug effects , Brain/physiopathology , Discrimination, Psychological/drug effects , Discrimination, Psychological/physiology , Disease Models, Animal , Electroencephalography , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Indoles/blood , Indoles/pharmacokinetics , Isoflurophate , Male , Memory Disorders/etiology , Memory Disorders/metabolism , Nootropic Agents/blood , Nootropic Agents/pharmacokinetics , Random Allocation , Rats, Sprague-Dawley , Receptors, Prostaglandin E, EP2 Subtype/metabolism , Recognition, Psychology/physiology , Status Epilepticus/complications , Status Epilepticus/metabolism , Status Epilepticus/psychology
SELECTION OF CITATIONS
SEARCH DETAIL